Antibodies

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

Actoxumab (anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab (anti-Cdiff Toxin A) prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile.

ASC06-IgG1

ASC06-IgG1

Astegolimab (anti-IL-1RL1) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab (anti-IL-1RL1) has the potential for chronic obstructive pulmonary disease (COPD) research.

Astegolimab (anti-IL-1RL1) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab (anti-IL-1RL1) has the potential for chronic obstructive pulmonary disease (COPD) research.

Astegolimab (anti-IL-1RL1) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab (anti-IL-1RL1) has the potential for chronic obstructive pulmonary disease (COPD) research.

Astegolimab (anti-IL-1RL1) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab (anti-IL-1RL1) has the potential for chronic obstructive pulmonary disease (COPD) research.

Bapineuzumab (anti-APP) is an anti-β-amyloid protein (APP) recombinant monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD).Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

BHQ880 (anti-DKK1) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone